Latest in Lung, Genitourinary, Gynecologic, and Breast Cancers From ASCO 2022: Drs Charu Aggarwal, Bradley McGregor, Robert Coleman, and Kevin Kalinsky

EP: 1.Preview of ASCO 2022: Dr Everett Vokes

EP: 2.Gastrointestinal Cancers Recap at ASCO 2022: Dr Tanios Bekaii-Saab

Now Viewing

EP: 3.Latest in Lung, Genitourinary, Gynecologic, and Breast Cancers From ASCO 2022: Drs Charu Aggarwal, Bradley McGregor, Robert Coleman, and Kevin Kalinsky

OncLive^® will be LIVE with OncLive^® News Network: On Location at the 2022 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Today-

We are reporting from the 2022 ASCO Annual Meeting!

Get ready for highlights of some of the top news presented each day during the meeting—and soon we’ll speak with Drs Charu Aggarwal, Bradley McGregor, Robert Coleman, and Kevin Kalinsky, on what pivotal lung, genitourinary, gynecologic and breast cancer studies they are most excited about.

Welcome to OncLive^® News Network! I’m Caroline Seymour.

Treatment with trastuzumab deruxtecan doubled progression-free survival and reduced the risk of death by 36% compared with physician's choice of chemotherapy for patients with HER2-low, hormone receptor–positive metastatic breast cancer in findings from the phase 3 DESTINY-Breast04 study that were simultaneously published in the New England Journal of Medicine.

Ribociclib plus endocrine therapy led to a statistically significant improvement in progression-free survival in patients with hormone receptor–positive, HER2-negative unresectable or metastatic breast cancer with tumor progression following treatment with a CDK4/6 inhibitor in findings from the randomized phase 2 MAINTAIN trial.

A subgroup analysis of the phase 3 KEYNOTE-826 trial showed that pembrolizumab plus chemotherapy with or without bevacizumab prolonged progression-free survival and overall survival versus placebo plus chemotherapy with or without bevacizumab irrespective of bevaczumab use, histology, platinum use, and prior chemoradiation therapy and provided clinically meaningful benefits similar to the broader population of patients with persistent, recurrent, or metastatic cervical cancer.

Finally, rucaparib led to a significant improvement inprogression-free survival as first-line maintenance therapy in patients with ovarian cancer regardless of biomarker status in the phase 3 ATHENA-MONO trial.

Please be sure to check out more of our coverage from the 2022 ASCO Annual Meeting at OncLive.com.

That’s all for today.

Thank you for watching OncLive^® News Network: On Location, I’m Caroline Seymour.